The Patent Finder

Ipsen Biopharmaceuticals, Inc.

Also on record
Records under this name other than the patents Ipsen Biopharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 5 of 5 · Back to Ipsen Biopharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,258,864Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
Term ended
Term ended Aug 26, 2025 · USPTO record
Term endedTerm ended Aug 26, 2025USPTO record
US 8,133,862Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency
Term ended
Term ended Mar 31, 2025 · USPTO record
Term endedTerm ended Mar 31, 2025USPTO record
US 7,517,530Methods for treatment of insulin-like growth factor-1 (IGF-1) deficiency comprising administration of IGF-1 and growth hormone
Term ended
Ended no later than Sep 9, 2024 · USPTO record
Term endedEnded no later than Sep 9, 2024USPTO record
US 8,158,582Methods for treatment of insulin-like growth factor-1 deficiency
Lapsed on the fee record
Ended Apr 17, 2024 · USPTO record
Lapsed on the fee recordEnded Apr 17, 2024USPTO record
US 8,440,616Methods for treatment of insulin-like growth factor-1 deficiency
Lapsed on the fee record
Ended May 14, 2021 · USPTO record
Lapsed on the fee recordEnded May 14, 2021USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited